European Antibody Congress brochure .pdf



Nom original: European-Antibody-Congress-brochure.pdf

Ce document au format PDF 1.4 a été généré par Adobe InDesign CC 2014 (Macintosh) / Adobe PDF Library 11.0, et a été envoyé sur fichier-pdf.fr le 29/05/2015 à 11:47, depuis l'adresse IP 193.52.x.x. La présente page de téléchargement du fichier a été vue 4385 fois.
Taille du document: 2.3 Mo (27 pages).
Confidentialité: fichier public


Aperçu du document


11th Annual

9-11 November 2015
Congress Centre, Basel, Switzerland

Discover. Develop.
Get to market.
Created by

Part of

Co-located with

Partnered with

Supported by

terrapinn.com/EAC2015

“ EXCELLENT NEW RESEARCH IN THE AREA OF ANTIBODY
ENGINEERING. VERY INNOVATIVE. EXCELLENT LIST OF
SPEAKERS. BEAUTIFULLY ORGANIZED MEETING.”
CSO BIOMUNEX PHARMACEUTICALS

WHATS IN STORE FOR 2015
The European Antibody Congress is where pharma, biotechs, clinicians, researchers
& innovative start-ups gather to develop new strategies and partnerships to advance
antibody drug discovery, development, and commercialisation. Join the largest antibody
event focused on getting important new therapeutics and immunotherapies into the clinic
and see where antibody development is headed next.

Your Congress,
Your Way
Challenges affecting the whole sector will be
addressed in high-level plenary sessions,

N

Le

W

n
tio ive
bi vat
hi inno
Ex ring s.
er offe gie
id liers nolo
ov pp ech
Pr t su d t
n mee s an
tio ers vice
lu buy ser
So here

ew
Fo
c
an us
ad
an
e
tib d
in
Ta
g
od se
on
f
rg
s
i
or d im
es s
et
co
an ion
di
lo
20 p
s
s
d
g
fo co
em on
th y c
ro
r e ve
im 15
l
e
i
e
n
r
ar ry
ve
ap ic
rg m
ly a
ian
i
u
n
e
n
ph d
d
ut s
g ne
ics d
im c
a
c
se om
Po
m he
in iscu
u
c
p
st
t
an ro pu
no kp
o ss
er
th h
tib te ta
th oi
pr
e
er nt
od in tio
ow
es
c
ap
n
e
lin t
y
a
n
en
fo gi l b
ies
o
i
c
ta
rm ne io
.
ge
.
tio
tn
at er log
n
i
s
n
e
y
.
se
g
w
s
an tra
ss
io
d te
n.
ne gi
w es

Immunotherapy and Immune Checkpoint Antibodies,
Antibody-Drug Conjugate (ADC) Development,
Bispecifics & Novel Constructs, Early Discovery
& Analytics, Preclinical Development, CMC/
Developability, Manufacture & Purification,
Clinical Development & Trials, Novel
Applications for Antibodies and Platform
Technology Showcase.

l
ca
ni ,
:
cli ry
r ering and cove
tte Cov ical et dis
Be ent. eclin arg s.
& cont s, pr ics, t tion
er ll of ADC nalyt plica
gg d fu py, , a l ap
Bi acke thera turing nove
p
o ac d
ys
un uf an
da mm an ion
3
I
m t
d t, ula
an en eg
er pm r
nc lo
Ca eve
d

Tw
In
o
ev Dr
v
ex
en ink a
l
te
nd ing s R ua
ed Po ece
b
s
tim bre ter ptio le
Pr ns
e ak
N
e ,
to s
m and sen off- et
w
ee l
t s
t w un atio ite
o
ith che n S and rk
ot s w ess on
in
he i
i
r a ll e on site g
a
n
tte s
l
p
nd ure ong art
sid ies
ee pl
s. en
e ,
ty
of

branching off into targeted sessions, suited to your
specific interests.

Save money and book early @ terrapinn.com/EAC2015

10

REASONS TO ATTEND

Engage with 60+ high-level pharma and biotech including Seattle Genetics, Novartis, Roche, Pfizer,
Memorial Sloan Kettering, Medimmune, NBE Therapeutics, Genentech, Merrimack, Oxford Biotherapeutics,
Philogen, Janssen, and Cancer Research UK.

1
2

Learn from success stories in immunotherapy and immune checkpoint antibodies from Novartis, Pfizer and
Memorial Sloan Kettering.

3

Explore the newest methods of discovery, target identification, analytics and computational biology with
4-Antibody, Pfizer and Baker Lab Washington.

4

Top oncology clinicians such as Michael Postow and not for profit groups Cancer Research UK will help to
understand the clinical development process, covering key issues in clinical practice and partnering.

Get updated on the latest bispecifics, complex molecules and scaffolds by Medimmune, Roche, Abbvie
and Janssen.

5

Examine how to reduce costs of purification and manufacture and explore best practices in CMC and
developability from KBI, BTI A*, Synthon, Pall and Fujifilm Diosynth.

6

Meet like-minded industry experts specific to antibody therapeutic areas and antibody development
stages in the targeted conference sessions.

7

Hear how industry leaders like Genentech, Philogen, NBE therapeutics & Oxford Biotherapeutics
envision the future of ADCs as they explore developmental updates and new emerging technologies.

8

9

Benefit from numerous networking opportunities that bring together all congress attendees
with Two Drinks Receptions, offsite and onsite parties, an Evening Poster Presentation Session
alongside extended breaks and lunches.

10

Network with 400 international, antibody stakeholders over 3 days. Meet and do business
with representatives from big pharma, biotech, investors, clinicians and researchers.

Save money and book early @ terrapinn.com/EAC2015

“ HIGH SCIENTIFIC VALUE OF THE TALKS, KNOWLEDGEABLE
SPEAKERS, GREAT NETWORKING WITH EUROPEAN
ENTITIES, ESPECIALLY FOR US BASED COMPANIES”
VP AMBRX INC.

CO-LOCATED WITH

COST-EFFECTIVE BIOLOGICS FOR PAYERS, PRESCRIBERS AND PATIENTS
• Pharmacovigilance in biosimilars
• Pure-play perspective: Why the ‘wait-and-see approach’ is the best strategy for the small
cap companies
• 360° perspective panels consisting of industry panellists, physicians, pharmacists, patient
advocacy groups, payers, regulators and health authorities
• Considering the innovator when developing the biosimilar
• With its first approved biosimilar, what effect is the UShaving on the global regulatory
environment for biosimilars?
• How to implement regulatory guidelines into your product development strategy
• Navigating the world of patents and IP to get your biosimilar to market
• Naming conventions for biosimilars and subsequent labelling practices
• How quickly will biosimilars be adopted in clinical practice?
• Budget impact analysis of future healthcare uptake of biosimilars
More information is available at terrapinn.com/biosimilars2015

COST-EFFECTIVE BIOLOGICS FOR PAYERS, PRESCRIBERS AND PATIENTS











Containment strategies and chemical exposure control methods
Setting the scene for high potency innovation: The hazard versus the risk
Beyond the isolator: Considerations for full room filtration and containment
Outsourcing - Why? When?
How to ensure facilities and equipment are fit for purpose and avoid overdesigning
How to choose between new equipment and enhanced existing solutions for your high potency
API manufacturing needs
How best to manage legacy facilities when repurposing for high potency API manufacturing
Will continuous processing ever be a reality for high potency API manufacturing?
Enabling standardisation and cleaning validation for high potency API manufacturing processes
How to ensure your external partners are using the best equipment and methods for your projects
More information is available at terrapinn.com/HPAPI2015

SPOTLIGHT ON SPEAKERS
Dr Peter Senter, Vice President of Chemistry, Seattle Genetics
Dr Peter Senter has served as Vice President, Chemistry since September 2002 and in February 2009, Dr. Senter
was recognized as the company’s first Distinguished Fellow. He leads Seattle Genetics’ chemistry department,
which carries out research in antibody-drug conjugate technologies, including the development of potent drug
payloads, novel linker systems, conjugation methodology and mechanism of action studies. He is the Senior Editor
of Molecular Cancer and serves as an Affiliate Professor of Bioengineering at the University of Washington.
Dr Senter will give an exciting keynote session on the status of the ADC field and what might be in store for the
future including an overview of the technologies that have been most pivotal in the development of approved
ADCs, from clinical advancement to what partnerships and collaborative efforts have been formed to create
success in ADC development.

Dr Emma Lees, Vice President, Oncology Biotherapeutics, Novartis Institute for Biomedical
Research (NIBR)
Dr Emma Lees has over 25 years of experience in the field of oncology research and more than 16 years of industry
experience in therapeutic drug discovery and organizational leadership. Dr. Lees is the Vice President of Oncology
and Site Head for Emeryville at Novartis Institutes for Biomedical Research (NIBR). Her responsibilities include leading
internal, world-class research to identify novel oncology drug targets, development of appropriate assays for therapeutic
discovery, management of project progression through preclinical research, and interface with the preclinical and clinical
development. She serves as part of the global oncology leadership team, building the strategy and implementation of
the Oncology portfolio for Novartis, and has global responsibility for the oversight to the oncology biologics pipeline.
Dr Lees will be discussing precision oncology and how to best use genomics to correctly identify drug targets and
optimize the preclinical development of therapeutics.

Dr Hans-Peter Gerber, Vice President, Pfizer Worldwide Research & Development, Pfizer
Dr Hans-Peter Gerber is leading the Bioconjugate Discovery and Development group at the Oncology Research
Unit in Pearl River, NY, where he is building a program to develop novel biotherapeutic drugs, including antibody
drug conjugates and bi-specific compounds redirecting immune effector cells to the tumor environment. In 1995
he joined Genentech as a visiting scientist, where he spent 11 years in research studying the mechanisms involved
in the regulating blood vessel formation and developing therapeutic antibodies interfering with tumor growth. In
March 2006, he joined Seattle Genetics as head of the Translational Biology Department, where he contributed to
the development of therapeutic antibodies and ADCs.
Dr Gerber will present on how to best select targets, payloads and reduce off-target toxicity in alternative
modalities (ADC or Bispecific) when developing a new therapeutic platform, in this case redirected T-Cell targeting,
for the first time.

Dr Michael Postow, Medical Oncology Fellow Medicine, Memorial Sloan Kettering
Dr Michael Postow is a physician on the faculty at Memorial Sloan Kettering Cancer Center in the Melanoma and
Immunotherapeutics Oncology Service. He completed medical school at New York University School of Medicine
and internal medicine residency training at Brigham and Women’s Hospital/Harvard Medical School. He then
returned to New York City to pursue a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center
where he conducted research with Dr. Jedd Wolchok in melanoma and immunotherapy. He has participated in a
number of clinical trials involving immunotherapeutic agents, most notably leading a phase II study of the combination
of nivolumab and ipilimumab and organizing a trial combining radiotherapy and immunotherapy. The lead author in an
exciting new study on combining immunotherapy drugs ipilimumab (Yervoy™) and nivolumab (Opdivo™).
He will be covering the various clinical aspects involved in the development of immune checkpoint modulators and
whether antibody combinations are preferable.

Dr Christian Klein, Head of Oncology Programs, Roche
Dr Christian Klein, Distinguished Scientist is Head of Oncology Programs at the Roche Innovation Center Zurich,
Roche Pharmaceutical Research and Early Development, Switzerland specialized in the discovery, validation and
preclinical development of antibody based cancer immunotherapies and bispecific antibodies. During his >14
years at Roche he has made major contributions as research project leader to the development and FDA/EMA
approval of obinutuzumab, the preclinical development of four bispecific antibodies currently in active clinical
development: 1) CEA-IL2v immunocytokine RG7813 (Ph I), 2) anti-Ang-2/VEGF CrossMAb RG7221 in oncology
(Ph II), 3) anti-VEGF/Ang-2 CrossMAb RG7716 in ophthalmology (Ph I) and 4) CEA-CD3 T cell bispecific antibody
RG7802 (Ph I), as well as the development of Roche’s novel proprietary bispecific antibody platforms e.g. the
CrossMAb technology. He’ll be exploring engineering, design and preclinical development of novel formats,
particularly the challenges and benefits of T-Cell Bispecific antibodies.

SPOTLIGHT ON SPEAKERS
Dr Ulf Grawunder, CEO, NBE Therapeutics
Dr Ulf Grawunder is founder and CEO of NBE-Therapeutics, a Swiss Biotech company incorporated in 2012,
which focuses on the development of “next-generation” antibody-drug conjugates for cancer therapy. Prior to that,
Ulf co-founded 4-Antibody in 2004, a Swiss therapeutic antibody engineering company, where he initially served
as CEO and later as CSO, until the company was sold to US-based Agenus in 2013.
Ulf is member of a number of national and international boards of for profit and non-profit organizations, including
the scientific advisory board of the Bavarian Immunotherapies Network, BayImmuNet, Germany and the Board of
the Swiss Biotech Association. Dr Grawunder will be discussing new methods of ADC development to improve
efficacy and decrease tumor resistance.

Dr Keith Wilson, CSO, Oxford Biotherapeutics
Dr Keith Wilson has over 20 years’ experience of life sciences research and development, specializing in oncology
and immunology. He joined Oxford BioTherapeutics from Abbvie where he was Global Leader, Antibody Drug
Conjugates and Director, Biologics Technology, and was responsible for corporate ADC strategy with multiple
programs in pre-clinical and clinical development, as well as leading a large multi-functional discovery team.
Oxford BioTherapeutics is a clinical stage biotechnology company that is developing a range of innovative
antibody based therapeutics, including antibody-drug conjugates (ADCs), for the treatment of cancer. Dr Wilson
will be discussing precision cancer therapy ADCs with novel antibody and cancer toxin technologies, target
discovery for optimal ADC activity, using partnership and collaborations to advance ADC development into the
clinic and improving efficacy of ADCs by identifiying antigen targets from a wide range of cancer types.

Prof Dr Dario Neri, Professor, Department of Chemistry & Applied Biosciences, ETH Zurich;
Founder, Philogen
The research of the group of Dr Neri focuses on the engineering of therapeutic antibodies for the therapy of cancer
and other angiogenesis-related disorders. Other research activities include the chemical proteomic discovery of
novel vascular markers of pathology and the development of DNA-encoded chemical libraries. Dario Neri is a
co-founder of Philogen, a Swiss-Italian biotech company which has brought five antibody-based products into
multicenter clinical trials for the therapy of cancer and of rheumatoid arthritis.Dr Neri will be giving an update on
armed antibodies for the treatment of cancer and of chronic inflammation focusing on transferring therapeutics
from the bench to the clinic.

Prof Thomas Powles, Clinical Professor of Genitourinary Oncology, Barts Cancer Institute
Prof Powles is the lead for solid tumor research at Barts Cancer Institute and also leads the genitourinary cancer
group at BCI. His work focuses on a spectrum of clinical studies from phase I to randomised phase III. The
majority of the studies are translational phase II studies investigating novel targeted and immune therapies. They
exploit functional imaging and tissue collection. Alongside these trials, his research focuses on correlation of novel
biomarkers and aims to define markers that are of prognostic value and can predict response or resistance to
therapy. His group recently published research in Nature on a breakthrough Anti-PD-L1 immunotherapy treatment in
the treatment of metastatic bladder cancer. Prof Powles will be looking at what we can learn from his recent study
when sending novel formats into the clinic, as well as how to respond with new safety and efficacy guidelines of
immunotherapies and how to use new immunotherapy alongside other modalities to improve patient outcomes.

Dr Volker Schellenberger, President & CEO, Amunix
Volker Schellenberger is a co-founder of Amunix and currently serves as President and CEO. Dr. Schellenberger
has extensive industry experience in protein engineering and drug discovery. Previously, he headed the Protein
Engineering department at Genencor, where he invented combinatorial consensus mutagenesis, selection by microcompartmentalization, as well as mutator technology. In addition, he initiated and led collaborations with Seattle
Genetics that focused on antibody-enzyme fusion proteins. Prior to his work on biotherapeutics, Dr. Schellenberger
directed projects optimizing enzymes for industrial applications as well as microbes for metabolic pathway
engineering. Dr. Schellenberger is the author of over 40 scientific papers and an inventor on more than 70 issued and
pending patent applications. He is also the recipient of the Karl Lohman award of the German Society of Biochemists.

BIG TOPICS
This year’s conference will cover:
IMMUNE CHECKPOINT ANTIBODIES AND IMMUNOTHERAPY

Immunotherapy drugs are considered to be more efficient than the traditional options, and they are set to
be used for the treatment of a variety (around 60%) of cancer types during the next ten years. Using T-Cells
to reengage the body’s immune system has been more and more widely reported and is set to revolutionise
the way cancer is treated. A focused session looking at developing immune checkpoint antibodies as
well as how to get T-Cell therapies from bench to bedside and more will take place this year. We will look
at developing novel immunotherapies and how they behave in the clinic with case studies from Novartis,
Roche and Memorial Sloan Kettering Hospital as well as a very special presentation from Pfizer discussing
their new immunotherapy for the first time.
ADCs

The major challenges of developing ADCs from tackling the bottleneck from bench to bedside will be
addressed. Looking at novel payloads, decreasing side effects, target identification and preclinical
development. An overview of the field will be given by Peter Senter from Seattle Genetics and followed by
informative case studies from NBE Therapeutics, Oxford Biotherapeutics and other leading minds in the field
from both pharma and biotech.
BISPECIFIC ANTIBODIES

Focusing on the next generation of cancer application and autoimmune disease therapies. We will look at
the mechanism of action of bispecifics in humans, new technologies, novel constructs and engineering
bispecifics while considering later stages of clinical application.
DISCOVERY AND DEVELOPMENT

New methods and technologies will be explored, such as advances in computational biology, analytics,
and target discovery. Mass spectrometry, molecular assessment, structural analysis, stability and scalability
will all be discussed. We will explore what the most important factors are in developing antibodies of every
format from mAbs to ADCs with a view to clinical success and commercialisation.
CMC, MANUFACTURE & PURIFICATION

Addressing the challenges of developing a molecule which is stable producible and has a high yield. Experts
will discuss developing biologics from start to finish, ensuring GMP and quality at a commercial scale, new
animal models, and stability. Manufacture and purification of ADCs, continuous manufacture of antibodies
as well as new cost effective methods of antibody purification will also be covered.
CLINICAL DEVELOPMENT

How to ensure clinical viability of antibody drugs will be the focus of this session with case studies from the
leading researchers, clinical oncologists and thought leaders. Topics such as ensuring clinical development
through innovative partnering, considering immunogenicity, and decreasing costs in trials will be discussed.
PLATFORM TECHNOLOGY SHOWCASE

A new targeted session exploring the most innovative new platform technologies being developed towards
antibody engineering and development will take place.
THE FUTURE

From huge advances in cancer therapies and immune system modulation to recent developments in
treating infectious disease, inflammation, T-Cell biology, neurological applications, and creating vaccines:
antibody based drugs are set to have profound effects in every area of medicine in the very near future. We
will be looking to the future of new targets, constructs and applications in 2016. Janice Reichardt will give a
closing keynote on antibodies to watch for 2016.

DAY 1 – MONDAY 9 NOVEMBER, 2015
08:00

Registration opens

09:00

Chair’s opening remarks
Dr Alain Beck, Senior Director CIPF, Associate Editors, mAbs

Opening Keynotes: New antibody formats and targets
09:05

The past, present, and future of antibody-drug conjugates
• The overall status of the field and future expectations
• An overview of  technologies that led to the currently approved ADCs and new technologies under investigation for future ADCs
• Clinical advancements
• What partnerships and collaborative efforts have been formed to create success in ADC development?
Dr Peter Senter, Vice President Chemistry, Seattle Genetics

09:25

Precision oncology: Treating cancer using targeted therapies that pinpoint genetic mutations
• Identifying pathways most commonly associated with cancer
• Screening compounds to identify ones with greatest potential to impact pathway
• Identifying biomarkers and create diagnostic tools
• Targeting patients most likely to benefit from therapy
Dr Emma Lees, Vice President, Oncology Biotherapeutics at Novartis, Novartis Institutes for BioMedical Research (NIBR)

09:50

Matching target biology with the optimal therapeutic modality in oncology
• From antibody drug conjugates to bispecific, redirected T-cell targeting
• Payload selection, target biology and reduction in off-target toxicity of ADCs
• Progress made with bispecific, redirected T-cell targeting programmes
Dr Hans-Peter Gerber, Vice President, Pfizer Worldwide Research & Development

10:15

Reserved for Platinum Partner

10:40

Networking refreshment break

11:40

Roundtable Discussion Session
16 senior level tables hosted by thought leaders on key challenges and opportunities antibody drug development. Participants
are invited to join in the small-group discussions on a topic of primary importance to them. See Page 13 for details

Analytics for ADCs
Alain Beck, Senior Director, Antibody
Physico-Chemistry, CIPF; Associate Editor,
mAbs

A needle in a haystack. Shortcuts
to visualising and validating
biomarkers for disease diagnosis and therapy
Jeremy Clarke & Richard Willock,
Asterand Bioscience

Using human tissue-based research solutions
for antibody drug discovery

How to use bioinformatics programmes for
target discovery

Designing ADCs

The next generation of antibody conjugates:
moving beyond cytotoxic payloads

Dr George Badescu, Scientific Director –
Conjugation & Protein Engineering, Abzena

Optimising GMP at a commercial scale

Dr David Rabuka, Head of Global R&D,
Chemical Biology, Catalent

Optimising drug delivery

Non-radioactive potency assays for ADCs
Dr Alexis Rossignol, R&D Project Manager,
Clean Cells

CMC and developability considerations
Dr Prathima Acharya, KBI Biopharma

Tackling the challenges of Target Discovery

Partnering and licensing: How to get your
antibody to market quickly and cost-effectively

DAY 1 – MONDAY 9 NOVEMBER, 2015
12:45
14:15

Networking lunch
ADCs

Immune checkpoint antibodies & bispecifics

Tackling the bottleneck: From bench to bedside

Immune checkpoint antibodies and immunotherapy

Novel enzymatic conjugation for developing nextgeneration antibody drug conjugates
• Sortase enzymes provide a robust and efficient means
to attach toxic payloads to antibodies
• Highly site-specific conjugation yields homogenous
drug product with defined efficacy, PK properties and
safety profile.
• Production of dual payload ADCs may help address
resistance and provide opportunity to tackle tumor
heterogeneity and quiescence
Dr Ulf Grawunder, CEO, NBE Therapeutics

Clinical development of immune checkpoint
modulators
• Is combination of antibodies necessary?
• How do we best sequence these antibodies?
• How do we image patients for the effects?
• How can we best assess side effects?
Dr Michael Postow, Medical Oncology Fellow Medicine,
Memorial Sloan Kettering

14:35

Selecting payloads for antibody drug conjugates
• Choice of payloads to overcome resistance
mechanisms
• Identification and evaluation of novel ADC payloads
• Creating next generation ADCs, making use of
additional payloads with the potential to address
current shortcomings
Dr Vishal Verma, Scientist, Medicinal Chemistry,
Genentech

Anti-PD-L1 immunotherapy treatment in the
treatment of metastatic bladder cancer
• What can we learn from this when sending novel
formats into the clinic?
• How do we respond to new safety and efficacy
guidelines of new immunotherapies?
• How can we use new immunotherapy alongside other
modalities to improve patient outcomes?
Prof Thomas Powles, Clinical Professor of Genitourinary
Oncology, Barts Cancer Institute

14:55

Optimized Site Specific ADC Generation
• Enabling precise, and programmable, site-specific
chemical protein modification
• The development of novel conjugation chemistry resulting
in ADCs with enhanced stability
• Linker chemistry that optimizes the potency of the
cytotoxic payload
Dr David Rabuka, Head of Global R&D, Chemical
Biology, Catalent

CTL cell therapy in cancer: Driving toward the clinic
• Complete and durable clinical responses to leukaemias
through (CAR) T Cells
• Safety considerations when adopting novel formats
into the clinic
Dr Alfonso Quintas, Global Clinical Leader, Oncology,
Novartis

15:15

Innovation in cancer
Precision cancer therapy ADCs with novel antibody
and cancer toxin technologies
• Oncology target discovery for optimal ADC activity
• Using partnership and collaborations to advance ADC
development into the clinic
• Improving efficacy of ADCs by providing a unique
range of validated, novel antigen targets identified from
a wide range of cancer types
Dr Keith Wilson, CSO, Oxford Biotherapeutics

15:30

Networking refreshment break

16:15

XTEN Drug Linkers with Precisely Controlled
Chemical Structures for High Drug Loads and
Optimized Tissue Uptake
• Size-optimized polymer linkers
• Enhanced tumor uptake triggered by extracellular
proteolysis followed by intracellular drug release
• Solubilization of hydrophobic payloads
Dr Volker Schellenberger, President & CEO, Amunix

Immune checkpoint technologies
Reserved for supporting partner

Bispecifics
A novel T-cell bispecific antibody platform
• Introduction of a novel IgG-based T-cell bispecific
(TCB) antibody platform enabled by the CrossMAb
technology
• Engineering, design and advantages as compared to
existing T-cell bispecifics platforms
• Preclinical properties of the CEA-CD3 TCB (RG7802)
currently in Phase 1 clinical trials
Dr Christian Klein, Head Oncology Programs, Roche

DAY 1 – MONDAY 9 NOVEMBER, 2015
16:35

The future of ADCs
Armed antibodies for the treatment of cancer and of
chronic inflammation: From the bench to the clinic
• Comparative evaluation of different types of armed
antibodies
• Quantitative evaluation of targeting
• Emerging clinical results
Prof Dr Dario Neri, Professor, Department of Chemistry
& Applied Biosciences, ETH Zurich; Founder, Philogen

16:55

Developing ADCs for non-oncological applications
• Using ADCs to treat inflammatory disease
• The targeted delivery of small molecule modulators for
indications beyond oncology
• Developing new ADC carriers
Dr Feng Wang, Principal Investigator, Calibr - California
Institute for Biomedical Research

Bispecific Antibodies: strategies, considerations
and challenges
• Novel approaches to produce bispecific antibodies in a
single cell
• Strategies to screen for bispecific antibodies
• Designing bispecific antibodies to match the proposed
mechanism of action and intended clinical application
Dr Christoph Spiess, Senior Scientist, Genentech

Engineering bispecifics and novel formats
Improving target cell specificity using a novel
monovalent bispecific IgG design
• What are the main challenges in increasing accuracy of
bispecifics?
• What are the most important steps that need to be
taken during design?
• How can this novel method improve preclinical and
clinical success of bispecific drugs?
Dr Partha Chowdry, Principal Scientist, Medimmune

16:55

Decreasing side effects in ADCs
• Maintaining stability and increasing circulation time
• What are the most important safety considerations
when developing ADCs?
• How can we improve preclinical development steps to
make them safer once they enter the clinic?
Dr Florence L’Hospice, Director, Pharmaceutical
Operations, Innate Pharma

Tumour antigen-binding bispecific antibodies for
cancer treatment
• New applications for bispecifics in experimental cancer
therapy
• Molecules that bind different cell surface proteins to
achieve more complete blockage pathways
• Application of bispecifics in the clinic, what method
works best to accelerate this process?
Dr Ulrich Brinkmann, Expert Scientist, Roche Pharma
Research & Early Development, Roche Innovation
Center Penzberg, FRG

17:35

Advances in ADC design for cancer treatment
• Have ADCs fulfilled the promise of patient benefit?
• Current developments in ADCs utilising ImmunoGen’s
maytansinoid platform
• What’s next in designing effective, well-tolerated
ADCs?
John Lambert, CSO & Executive VP, ImmunoGen

Evaluating clinical data to discover how DvD
bispecifics behave in humans
• Identification of anti-ErB2 dual variable domain
immunoglobulin proteins with unique activities
• How are DvD bispecifics impacting disease in terms of
the pD markers?
• What is the mechanism of action?
Dr Tariq Ghayur, Senior Principal Scientist & Research
Fellow, Abbvie

17:55

Chair’s closing remarks

18:00

Networking drinks reception
See website for most up-to-date agenda

Save money and book early @ terrapinn.com/EAC2015

ROUNDTABLES
DAY 1 – MONDAY 9 NOVEMBER, 2015

Analytics for ADCs

Partnering and licensing:
How to get your antibody
to market quickly and costeffectively

Alain Beck, Senior
Director, Antibody
Physico-Chemistry, CIPF;
Associate Editor, mAbs

A needle in a
haystack. Shortcuts to
visualising and validating
biomarkers for disease
diagnosis and therapy
Jeremy Clarke &
Richard Willock,
Asterand Bioscience

Non-radioactive potency
assays for ADCs

Optimising drug delivery

As there is so much competition in the
antibodies sector it is now more important
than ever that you keep up to date with the
latest developments and what competitors are
working on. The European Antibody Congress
roundtable discussions do just this, they provide inside
information that you can’t get anywhere else.

Optimising GMP at a commercial
scale

Dr Alexis Rossignol, R&D
Project Manager, Clean Cells

Using human tissue-based
research solutions for antibody
drug discovery

Take time to hear from leading providers and
authorities in the antibody space and exchange
knowledge and ideas with your peers in these
facilitated discussion sessions.
Confirmed roundtable discussions include:
Tackling the challenges of
Target Discovery

How to use bioinformatics
programmes for target discovery

The next generation
of antibody conjugates:
moving beyond cytotoxic
payloads
Dr David Rabuka, Head
of Global R&D, Chemical
Biology, Catalent

CMC and developability
considerations
Designing ADCs
Dr George Badescu,
Scientific Director –
Conjugation & Protein
Engineering, Abzena

Dr Prathima Acharya,
KBI Biopharma

To host a roundtable, speak to Jessica
e/ jessica.robinson@terrapinn.com

DAY 2 – TUESDAY 10 NOVEMBER, 2015
08:00

Registration opens

09:00

Recap of Day 1 and opening remarks
for Day 2

Recap of Day 1 and opening remarks
for Day 2

Early Discovery and Analytics

CMC/Developability

Computational biology

From Start to finish

09:15

Computational biology in the
discovery and development of
antibodies

Humabodies: ‘Right First Time’
- Human VH Fragments from a
Transgenic Mouse

• Using new technology and
collaboration to improve early
development
• How can intracellular cascades
increase precision of assays?

• Harnessing the natural process
of B cell maturation to generate
fully human VH fragments ready
for development into clinical
candidates

• Improvements in technology in
discovery & development and
how to use them

• Rapidly generating antibody
fragments with improved
developability attributes

Dr Alexey Lugovskoy, Vice
President, Therapeutics, Merrimack
Pharmaceuticals

• Target discovery for dermatology,
oncology and ADCs for local
action and decreased toxicity
Dr Thomas Sandal, VP of
Preclinical Development and Protein
Engineering, Crescendo Biologics

09:40

Antibody informatics for drug
discovery
• Advancing specificity  and safety
for drug development
• Using antibody informatics to
improve biophysical properties
• Predictive structural tools for
biotherapeutics industry
Dr Bojana Popovic, Senior
Scientist, Medimmune

Developing a molecule which
is stable/producible/has a high
yield
• New methods in CMC and
developability to create a
successful biologic molecule
• How to form partnerships to get
your antibody to manufacture and
market quickly
• Streamlining your pipeline to
develop and manufacture drugs
more efficiently and easily
Representative from KBI
Biopharma

10:05

Reserved for Supporting Partner

Using serum compatibility and
developability analyses to select
bispecific antibodies
• How to increase developability
of bispecifics using serum
compatability
• Selection of bispecifics when
considering later clinical stages
• What are the most important
parameters to consider when
selecting bispecific antibodies?
Dr Mark Chiu, Associate Director,
Multispecific Biologics Engineering,
Janssen

10:30

Networking refreshment break

Introduction from Chair

Platform Technology Showcase

A new targeted session exploring
the most innovative new platform
technologies being developed
towards antibody engineering and
development will take place.
Antibody drug developers will have
the chance to see innovative pitches
of new technologies that could help
them get their pipeline to the next
level.
See Page 17 for details

DAY 2 – TUESDAY 10 NOVEMBER, 2015
Analytics
11:40

How new mass spectrometry methods are changing
developability

Old target — new mode of action: how to make
extremely potent anti-ErbB2 agents

• Using OptimAbs and OptimADCs platforms to speed
up clinical development and increase therapeutic
potential

• Creating an intermolecular trap for ErbB2 to achieve
pan-ErbB inhibition

• Identifying critical quality attributes (CQA) based on
emerging analytical and structural methods

• Engineering novel cancer therapeutics with high
tumoricidal activity while avoiding adaptive resistance
and lowering side effects

• Transforming antibodies and ADCs into drug
candidates which are structurally optimised
Dr Alain Beck, Senior Director, Antibody PhysicoChemistry, Centre d’Immunologie Pierre Fabre;
Associate Editor, mAbs

12:00

Novel Constructs

Practical considerations in manufacturability
• Assessing and selecting molecules with CMC
development in mind
• Leveraging platform processes and methods to
significantly increase speed to FIH

• Eliciting apoptosis in ErbB2-addicted tumors

Dr Rastislav Tamaskovic, Plückthun’s lab, Department
of Biochemistry, University of Zurich

From a new analysis of IgG stability to mutants and
formulations
• Best practice for checking complex molecules for
mutations, lifespan and shelf life

• Stage-appropriate investments in manufacturability

• How to best apply kinetic analysis to predict the
stability of molecules

Dr Tanya Shang, Senior Principle Scientist, Analytical
R&D, BioTherapeutics Pharmaceutical Sciences, Pfizer

• Assessing an effect of formulation on kinetic stability of
antibodies
Dr Erik Sedlak, Associate Professor, Department of
Biochemistry, P.J. Safarik University

12:20

Improving product yield, stability, and binding
capabilities for various construct design parameters

Manufacture & purification

• Impacts of bispecific construct design variation on
production and function

Are all recombinant proteins equal? A cell line
development perspective

• Bispecific antibody facilitated targeting of the nanocells
to cancer cells

• Are there differences in the capability of a host cell line
to express a ‘difficult to express’ protein?

• Fusion protein development for targeting in a noncancer related indication cytokines for the treatment of
type 2 diabetes

• At what stage in the cell line development process
is a first true read out of productivity and product
characteristics possible?

Dr Karin Taylor, Research Scientist, University of
Queensland

• When can material be made available to feed other
development stages?
Dr Alison Porter, Head of Mammalian Cell Culture
R&D, Fujifilm Diosynth Biotechnologies

12:40

Rosetta, a new programme for antibody analytics
• Using Rosetta for protein design. methods in making a
new protein from scratch
• Targeting a specific receptor binding site to tackle
influenza using proteomic software
• New methods in protein analytics and how they can be
applied to biologic drug development
Dr Eva-Maria Straunch, Acting Instructor and
Translational Investigator, Institute of Protein Design, Baker
Lab, University of Washington

13:00

Networking lunch break

Continuous production and purification of complex
molecules
• ADC process development and scale-up strategy from
early phase development to commercial
• How to ensure safe, effective and reliable
manufacturing
• Tackling the main challenges of purifying ADCs
Dr Michel Eppink, Head of Downstream, Synthon

DAY 2 – TUESDAY 10 NOVEMBER, 2015
14:35

Target discovery
Target discovery for the production of ADCs: new
data from Genentech

• Five industry trends integrated in a new approach to
IgG purification:

• Novel target for AML

• Disposables, continuous processing, flow-through,
without columns, without protein A

• Targeting stem cells in colon cancer
• Matching the linker-drug to the target and indication
Dr Andrew Polson, Senior Scientist, Genentech

14:55

A new paradigm and non-protein A platform for
therapeutic IgG

• All new data from case studies with a Blockbuster
Biosimilar
Pete Gagnon, Project Director, Downstream Processing
Group, Bioprocessing Technology Institute in Singapore

Using DNA Transposon technology  for efficient
mammalian-cell antibody library display

Strategies in bioprocessing handling, analytical
characterization & outsourcing

• A novel and highly efficient non-viral antibody
discovery and engineering platform.

Reserved for supporting partner

• Display of full-length antibodies on the surface B
lymphocytes, i.e. their natural environment.
• Seamless integration of functional screening due
to built-in switch between surface and secreted
expression.
Dr Roger Beerli, CSO, NBE Therapeutics

15:20

Developing PD-L1 checkpoint antibodies using a
novel discovery platform

Manufacturing & Platform Flexibility Through
Continuous Chromatography Processing

• Generating high quality therapeutic antibody drug
candidates quickly using a high-throughput approach
incorporating human antibody libraries

• Using continuous processing techniques to lower the
cost burden of disposable processing

• New methods in discovery and preclinical checkpoint
antibody programs targeting multiple checkpoints
• Identifying development programs to be in a position
to file investigational new drug applications
Dr Mark van Djik, Chief Technology Officer, 4-Antibody

• Integrating chromatography and filtration unit
operations
• Simple, quick process development of continuous
chromatography
• Applying a range of purification chemistries for
platform variation
Dr Marc Bisschops, Principle Scientist, Continuous
Processing & Rob Noel, Business Development Manager,
Pall Life Sciences

15:45

Networking refreshment break

Regulation & intellectual property
16:30

Latest European Patent Office guidelines and what they mean for mAbs, ADCs and multispecifics
Helena Domingues, Examiner, European Patent Office

16:50

FDA Update: Antibody therapeutics focusing on ADCs, bispecifics and cancer immunotherapies
Dr Marjorie Shapiro, Chief, Laboratory of Molecular and Developmental Immunology, Division of Monoclonal Antibodies,
CDER/FDA

17:10

POSTER SESSION
Informal, interactive presentation and discussion of diverse topics in the field of antibody discovery, development,
manufacture and trials. Authors are invited to submit proposals relating to innovative projects, best practices and original
research findings.
Refreshments will be served throughout

17:50

Networking drinks reception
See website for most up-to-date agenda

Save money and book early @ terrapinn.com/EAC2015

PLATFORM TECHNOLOGY SHOWCASE
Seeking partnership, investment, licencing or looking to sell your technology?
Want to hear about the latest innovative platforms? Looking to invest?

A new targeted session exploring the most innovative new
platform technologies being developed towards antibody
engineering and development will take place.
Antibody drug developers will have the chance to see
innovative pitches of new technologies that could help
them get their pipeline to the next level.
Ten 20 minute presentations showcasing innovative
new platform technologies will take place alongside
the main scientific conference to a targeted room of
professionals.

Do you have a platform technology? You could be one of the 10 companies who will have
the chance to pitch to a biotech and pharma audience.
Hear about the latest pioneering platform technologies: Sit in on the pitching session to
what is out there and see if you could take your antibody development process to the next
level.
Audience Participation: Give feedback, ask questions, make connections with innovators
and perhaps form a new partnership.
See below for more details on how to get involved to get your technology in front of the
right people.

Do you have a platform technology that you want to promote or sell? Are you looking for partnership,
investment and licencing from big pharma and biotech companies?
If so, keep reading…
As part of the inaugural Platform Technology Showcase, we are offering you the opportunity to apply for one of ten 20
minute pitching slots available on Tuesday 10th November 2015. Each pitching slot consists of a 15 minute pitch and 5
minutes for questions from an audience of pharma, biotech and investors.

To apply, speak to Derek on
t/ +44 207 092 1297 e/ derek.cavanagh@terrapinn.com

DAY 3 – WEDNESDAY 11 NOVEMBER, 2015
08:00

Registration opens

09:00

Recap of Day 2 and opening remarks for Day 3

Preclinical development
09:15

Optimisation of immune-stimulating antibodies
• Preclinical development of immune stimulating
antibodies with a view to later clinical stages
• Fc receptor interactions and antibody conformation
direct distinct modes of activity
• Using in-vivo models to predict efficacy and toxicity
Dr Ann White, Senior Research Fellow, University of
Southampton

Recap of Day 2 and opening remarks for Day 3

Future uses for antibodies
Infectious Diseases
Broadly toxin-neutralizing and bactericidal
antibodies to fight severe bacterial infections.
• Novel broad-spectrum Staphylococcus aureus toxin
neutralizing antibodies
• Bactericidal mAbs to fight multi-drug resistant E. coli
• Choosing the right antibody discovery platform for
individual targets
Dr Eszter Nagy, Co-Founder, President & CSO, Arsanis,
Inc. Managing Director, Arsanis Biosciences GmbH

09:40

Producing better ADCs using ThioBridge™
conjugation

Development of DART® proteins for infectious
disease applications

• From mouse antibody to human therapy

• Overview of DART platform and formats

Dr George Badescu, Scientific Director – Conjugation &
Protein Engineering, Abzena

• Activity of DARTs targeting HIV-infected cells for
cytolysis
• Targeting Influenza and Dengue Virus by neutralization
Dr Syd Johnson, Vice President Antibody Engineering,
Macrogenics

10:05

Preclinical development of antibodies for
transplantation, autoimmune and inflammatory
diseases
• Looking at various formats of molecules to achieve
specific properties
• Selecting molecules based on in vitro activity, in vivo
stability and lack of immunogenicity
• Ensuring a preferable toxicology profile in preclinical
development with clinical stages in mind
Dr Jiri Kovarik, Senior Research Investigator,
Autoimmunity, Transplantation & Inflammation, Novartis
Institutes for Biomedical Research (NIBR)

10:30

• Investigating the action of mechanism of antibodies
with typhoidal and non-typhoidal Salmonella
• The relationship between protective epitopes and
surrounding epitopes in Gram-negative bacteria
• The mechanisms through which antibody kills Gramnegative bacteria after vaccination
Prof Adam Cunningham, Professor of Functional
Immunity, University of Birmingham

Networking refreshment break

Clinical development
11:40

Antibodies and protection against invasive
Salmonella disease

Clinical development of AXL-ADC
• AXL as an ADC target
• Clinical candidate selection
• Activity of AXL-ADC in in vitro and in vivo models.
Dr Paul Parren, Senior Vice President and Scientific
Director, Genmab

Inflammation and Neurology
Targeting arthritic cartilage for immunotherapy and
early diagnosis
• Developing a therapeutic to specifically target arthritic
cartilage and specific and sensitive radiographic
biomarkers for early diagnosis of OA
• Minimising side effects, damage to the rest of the
body, increasing specificity
• Decreasing local dose and reducing cost of treatment
Dr Ahuva Nissim, Reader in Antibody and Therapeutic
Engineering Biochemical Pharmacology, William Harvey
Research Institute, Queen Mary University

DAY 3 – WEDNESDAY 11 NOVEMBER, 2015
12:00

Considering immunogenicity of IgGs and mAbs
in ensuring clinical viability of therapeutics

Reserved for supporting partner

• Evaluating clinically relevant immunogenicity
• Optimising treatments with respect to how much
you dose
• How to manage the use of these biologicals in clinic
Dr Theo Rispens, Group Leader, Department of
Immunopathology Research, Sanquin Research

12:20

Transforming antibody development via
innovative partnering
• How can partnerships between academia and
industry improve drug development?
• Using novel business models to progress the drug
pipeline and resurrect deprioritised candidates
• Working with Medimmune in development and
discovery; an update

Developing targeted CNS biotherapeutics and
approaching difficult membrane-associated
targets
• Utilizing the VNAR scaffold to engineer
differentiated products in a variety of formats
including monospecific and bispecifics
Dr Frank Walsh, CEO, Ossianix

Dr Robert Williams, Chief Development Scientist, Drug
Development Office, Cancer Research UK

12:40

How to decrease costs in trials
• Scaling up, addressing the challenges
Reserved for supporting partner

Brain shuttle platform to open the blood brain
barrier gate for biologics
• Blood brain barrier the challenges for CNS drug
delivery
• Brain delivery of biotherapeutics
• The pRED Roche Brain Shuttle Platform
Dr Per-Ola Freskgard, Vice Director and Expert Scientist
Neuroscience, Roche Innovation Center Basel
Switzerland

13:00

Networking lunch break
The future of antibodies

14:35

Antibodies to watch out for in 2016
• Record numbers of recombinant antibody products received first marketing approvals in 2014 and 2015.
Products that might be granted approvals in 2016 will be identified and discussed.   
• Phase 3 clinical study results for a record number of antibody therapeutics are due in 2015. Study results
will be compared and contrasted, and the question of which antibodies are likely to move to regulatory
review will be explored.  
• So far, few ‘next generation’ formats such as antibody-drug conjugates and multi-specific antibodies
have progressed to late-stage clinical studies. The current commercial pipeline of these promising
formats will be assessed.
Dr Janice Reichardt, Editor in Chief, mAbs

15:00

Thank you & closing remarks by Terrapinn

END OF CONGRESS

15:30
See website for most up-to-date agenda

Save money and book early @ terrapinn.com/EAC2015

“ GOOD. DIVERSE SELECTION OF PRESENTATIONS
INCLUDING TALKS WITH NEW INFORMATION WHICH IS
IMPORTANT.”
SVP & CSO AMPLIMMUNE

IT’S A NETWORKING EVENT
The European Antibody Congress recognizes the importance of networking and offers an
experience which allows you to do just that.

ROUNDTABLE DISCUSSIONS
With moderators to lead discussions on key topics, you will take
your engagement and learnings to a new level in this interactive and
results-driven setting.

NETWORKING RECEPTION
It’s not always about the conference sessions. Our themed evening
networking drinks receptions both at the conference venue and off-site
on days one and two will allow you to unwind with your peers and
continue conversations in good company.

SCIENTIFIC POSTERS
Share research with leaders in the antibody sector within the
dedicated Scientific Poster session. Posters allow for pharma,
biotech and academia to present previously unpublished work. Taking
place before the networking drinks on day two of the congress, it
will be possible for poster contributors to answer questions and gain
feedback. Refreshments will be served throughout.
Please see terrapinn.com/EAC2015 for further details.

NETWORKING LUNCHES
Our extended lunch periods will provide you with ample time to
network between sessions. These lunch formats allow for more
opportunities for casual conversations and introductions, without
compromising your time attending the conference sessions.

WHAT OUR
CUSTOMERS SAY
‘Good. Diverse selection of
presentations including talks with
NEW information which is important.’
SVP & CSO, AMPLIMMUNE

‘Excellent new research in the
area of Antibody Engineering. Very
innovative. Excellent list of speakers.
Beautifully organized meeting’
CSO, BIOMUNEX
PHARMACEUTICALS

‘High scientific value of the talks,
knowledgeable speakers, great
networking with European entities,
especially for US based companies’
VP, AMBRX INC.

‘The best global Antibody meeting’
SENIOR DIRECTOR, CIPF

‘Very useful overview of many biotech
players’ pipelines and projects. Easy
to reach, well organized.’
SENIOR SCIENTIFIC ADVISOR,
EFFIMUNE

‘Really good list of speakers and
very topical sessions; I also enjoyed
the size of the meeting (not huge),
which allowed for making new
connections.’

SENIOR SCIENTIST, ANTIBODY
DISCOVERY, JOUNCE THERAPEUTICS

WHO ATTENDS

Senior Principal Scientist and Research Fellow, AbbVie Bioresearch Center Inc Managing Director,
AbCheck R&D Team Leader, AbD Serotec Scientific Director – Conjugation and Protein Engineering,
Abzena Chief Executive Officer, Advanced BioDesign Deputy General Manager, Ajinomoto Co
Inc Managing Director, Aldevron CSO, Ambrx Scientific Director, Amgen Research Munich
Over 400 delegates will be attending this year from pharma, biotech, clinicians,
Spa Senior Vice President R&D and CSO, Amplimmune Vice President of Antibody Engineering,
academics, researchers and start-ups
Macrogenics Chief Development Officer, arGEN-X Principal Scientist, Asterand Bioscience Senior
Director of Business Development, Asterand U.K. Vice-president, Atlanpole Biotherapies
Here is a sample delegate list of those who attended last year:
Project Manager, Atlanpole Biotherapies Bioprocessing Applications & Scientific Manager, BD
Biosciences - Advanced Bioprocessing Patent Counsel, Bemido SA Senior Scientist, Clinical
Research, Biogen Idec Chief Scientific Officer, BIOMUNEX PHARMACEUTICALS Managing Director, BioPortfolio Lab Head of N.B.E. Discovery, Boehringer Ingelheim Pharma GmbH & Co.
KG Senior Vice President of Immuno-Oncology & Biologics Discovery, Bristol Myers Squibb Vice President of C.M.C, C.M.C. Ambrx Inc Director of N.P.O. Sourcing and Operations, Cannondale
Securities Llc Head of Research and Development, Catalent Pharma Solutions Chief of Laboratory of Molecular and Developmental Immunology, CDER, FDA Director, Molecular and Cellular
Biology, Centre d’Immunologie Pierre Fabre Senior Director, Antibody Physico-Chemistry, Centre d’Immunologie Pierre Fabre Head of Experimental Cancer Research Department, Centre
D’Immunologie Pierre Fabre Principal Scientist, Chemical Computing Group CEO, ChemPartner Director Biologics, ChemPartner Executive Director, ChemPartner R&D Project Leader,
Cisbio Bioassays Research and Development Project Manager, Clean Cells Group Leader & Lab Manager, Target Discovery, Compugen Ltd Director, Process Development, Cook Pharmica
CEO Managing Partner, Creoptix AG CTO, Managing Partner, Creoptix AG VP of Preclinical Development and Protein Engineering, Crescendo Biologics Ltd Chief Scientific Officer, Crystal
Bioscience Director of Cell Biology, CytomX Therapeutics, Inc CSO, CytomX Therapeutics, Inc Chief Scientific Officer, Debiopharm International Sa Deputy Director General, Development
Center for Biotechnology Senior Scientific Advisor, Effimune Head Of In Vitro Preclinical Development, ElsaLys Biotech Director, emdmillipore Associate Professor, ETH Zurich Patent Examiner
European Patent Office, European Patent Office Examiner, Joint Cluster Biotechnology, Immunology Directorate, European Patent Office Senior Scientist, Fraunhofer Gesellschaft Principal
Scientist, Fujifilm Diosynth Biotechnologies Vice President R and D, GamaMabs Senior Scientist, Genentech Senior Director and Staff Scientist, Antibody Engineering, Genentech Senior Vice
President and Scientific Director, Genmab Director Antibody Therapeutics Genomics, Institute of the Novartis Research Foundation CSO, Genovis AB Founder, Chief Executive Officer and
Chief Scientific Officer, Glycotope GmbH Director Science and Technology, GSK Directeur Général, Gustave Roussy Comprehensive Cancer Center General Manager, Histalim Director, Ibc
Generium/CellThera Pharm Chief Technology Officer, Icosagen Cell Factory OU Manager of Business Development, Immatics Biotechnologies Gmbh Chief Scientific Officer, Immunocore
Executive Vice President & Distinguished Research Fellow, ImmunoGen Director Antibody Platform, Innate Pharma Director of Pharmaceutical Operations, Innate Pharma Professeur des Universités
Praticien Hospitalie, Inserm Chief Executive, Investigación Aplicada, S.A de C.V Managing Director, Pharmalicensing & VP, Technology Marketplaces, Iptechex Pharmalicensing Chief Scientific
Officer, Isogenica Ltd Director Of Preclinical Operations, ITALFARMACO S.P.A. Head of Biologics Research, Biotechnology COE, Janssen Senior Director of Antibody Drug Discovery, Janssen
Associate Director, Multispecific Biologics Engineering, Janssen Research and Development Llc Senior Scientist, Antibody Discovery, Jounce Therapeutics, Inc. Chief Scientific Officer and
Head of Business Development, K.B.I. Biopharma Drug Metabolism and Pharmacokineties, LFB Biotechnologies Chief Executive Officer, M.A.B. Discovery Gmbh Editor-in-Chief, mAbs
Landes Bioscience Principal, Maschio & Soames IP Limited Operations Director, Maschio & Soames IP Limited Director, Maschio and Soames IP Senior Scientist, Oncology Research,
MedImmune Senior Director of Research and Development, MedImmune Director of Oncology Research, MedImmune Business Scout, Menarini Biotech S.R.L. Principal Scientist, Bioprocess
Development, Merck Business Developer Emerging Biotech Market, Merck Group Gmbh Director of Technical Development Biosimilars, Merck Serono Senior Director, Nanotherapeutics,
Merrimack Pharmaceuticals Vice President of Therapeutic Design, Merrimack Pharmaceuticals Senior Scientist, Merus BV. Antibody Group Manager, MI-mAbs / Aix Marseille Université
Founder and Chief Executive Officer, ModiQuest Research Expert Scientist, Molecular Partners AG Senior Consultant, N.D.A. Regulatory Science Ltd Associate Investigator, National Institute
of Cancer Research Distinguished Investigator and Attending Physician, National Institute of Cancer Research, National Health Research Institutes Genomics & Biomedical Data Lead, NHS
England Global Head Developability Assessment, Integrated Biologics Profiling, Novartis Head of Molecular Interaction Facility, NovImmune Sa CBO & Co-Chief Executive Officer, Numab AG CSO
and Co-CEO, Numab Ag Vice President Marketing Biopharmaceuticals Europe, Pall Life Sciences Director, Protein Discovery and Optimisation Group, Pfizer Vice President, Pfizer Worldwide
Research and Development. Senior Principal Scientist, Pfizer, Inc Chief Executive Officer, Pharmatching Director, PharmaVision Vice President Early Discovery, Pieris Ag Scientific Director R&D,
Quality Assistance Managing Director, Retrogenix Biomarker Experimental Medicine Leader, Senior Principal Scientist, Roche Senior Translational Medicine Leader, Roche Scientific Director,
Roche Managing Director, European Operations, SafeBridge Europe D.S.P. Laboratory Manager, SANOFI Project Manager of Custom Synthesis, Sanofi Aventis Research and Development
Scientific Affairs & Strategics Support, Sanofi Global Biotherapeutics Head of Product Development, Solvinax Vice President of Research, Sutro Biopharma Director of Chemistry, Sutro
Biopharma Vice President of Research, Sutro Biopharma Chief Operating Officer, Swiss Biotech Association Co-founder, Philogen Senior Scientist, Symphogen A/S Managing Director,
The Chemistry Research Solution Project Manager, Tillotts Pharma AG Director, Antibody Discovery, U.C.B. Associate Professor, Department of Internal Medicine, University Hospital of
Wuerzburg CSO, SpectraMab Assistant Professor, Section for Stem Cell Transplantation and Immunotherapy, University Of Kiel Professor of Immunochemistry, University of Southampton Chief
Scientific Officer, Viventia Bio Inc. Director of Research, Viventia Biotechnology Inc Senior Director, Wuxi App Tec Senior Research Director, Xencor, Inc. Chief Technology Officer, Zymeworks

6,00

3,00

SOLD

31

30

2,00

32

3,00

2,00

6,00

26

4,00

25

27

4,00

29
6,00

3,00

4,00

3,00

3,00

34

35

36

38

39

40

3,00

3,00

3,00

3,00

2,00

33

24

23

3,00

3,00

3,00

37

3,00

3,00

43

44

2,00

28

4,00

4,00

3,00

6,00

22

3,00

• Pharmaceutical manufacturers
• API/HPAPI manufacturers
• Handling and containment services
• Safety services
• Bioprocessing services and equipment
• CMOs

3,00

3,00

3,00

3,00

42

45

3,00

3,00

3,00

3,00

10

20

2,00

9

19

4,00

11

18

2,00

3,00

12

21

4,00

3,00

8

4,00

7

3,00

6

13

4,00

5

14

4,00

15

3,00

16

3,00

3,00

6,00

2,00

2,00

• Market access consultants
• Regulatory consultants
• Comparative analytics
• Platform technology
• CMOs
• Sourcing services

2,00

3,00

2,00

4,00

4

4,00

1

3,00

• Platform technology
• CROs
• CMOs
• Turnkey equipment providers
• Bioprocessing services and equipment
• Bio-informatics and computational biology

3,00

3,00

2

3,00

WHO EXHIBITS?

17
3,00

3,00

3

3,00

THE EXHIBITION

2,00

Conference Rooms

41

46

2,00

2,00

RESERVED
AVAILABLE

Updated 8 May

WHY EXHIBIT?

GET INVOLVED

• Generate new business leads

• Book a stand

• Build brand presence and awareness

• Join our digital marketing campaign

• Forge strategic partnerships and joint
ventures

• Take part in pre-event networking

• Showcase latest products

• Invite your clients

• Promote new services to prequalified
clientele

• Help shape the event plans
• Book prospective meetings onsite

Breakout Rooms

CONFIRMED 2015 EXHIBITORS
STAND NO.

COMPANY

STAND NO.

COMPANY

STAND NO.

COMPANY

1

Asterand

13

Pall

34

Catalent

7

LFB Biomanufacturing

15

Clean Cells

35

Myoderm

8

Sycomore

17

Aldevron

36

Genovis

10

Agilent

19

DrugDesigntech

37

Maschio and Soames

11

KBI

20

FPS Pharma & Food Systems

42

Quality Assistance

12

Fujifilm Diosynth

33

Horiba

43

Abd Serotec a Bio Rad Company

SPONSORSHIP AND
EXHIBITION PACKAGES
PLATFORM
TECH PACKAGE

2

Added on request

1

9 sqm

Purchased by sqm
– 6 up to 24

PLATINUM

Keynote Plenary
Presentation or Interview

1

Track Presentation

1

1

Roundtable Host

2

1

1

On-Floor Demonstration

2

1

1

Access to Networking
Manager

Up to 12 meetings

Up to 8 meetings

Up to 5 meetings

Lead generation services

2 emails

1 email

Newsletter

Delegate passes

6

3

Exhibition booth

24 sqm

12 sqm

Platform tech pitch

GOLD

EXHIBITION

BENEFITS

SILVER

1

Can’t find a package that’s right for you?
Talk to Derek about tailoring something to meet your exact needs.
Derek Cavanagh t/ +44 207 092 1297 e/ derek.cavanagh@terrapinn.com

REGISTER YOUR PLACE TODAY

The earlier you book the more you’ll save.
For the latest price see
terrapinn.com/EAC2015

Delegate Booking
Package

Before
29-May-15

Before
12-Jun-15

Before
21-Aug-15

Before
11-Sep-15

Before
02-Oct-15

Before
23-Oct-15

Final Price

Standard
Package

£1620
SAVE £1348

£2160
SAVE £810

£2430
SAVE £540

£2565
SAVE £405

£2700
SAVE £270

£2835
SAVE £135

£2,970

Academic
Package

£815
SAVE £669

£1080
SAVE £405

£1215
SAVE £270

£1285
SAVE £200

£1350
SAVE £135

£1415
SAVE £70

£2,015

Poster

£50

£50

£50

£50

£50

£50

£50

BOOK NOW
Register at
terrapinn.com/EAC2015
Or call +44 (0) 207 092 1210

BRING YOUR TEAM
With three days packed full of great content
and networking opportunities, you can't
possibly cover it all alone!
Bring your team and get an extra discount.
Call +44 (0) 207 092 1210

SPONSORS

EXHIBITORS

Event Partners

Sponsors

Exhibitors

Media Partners

For sponsorship and exhibition opportunities, please contact Derek Cavanagh
t/ +44 (0) 207 092 1297 e/ derek.cavanagh@terrapinn.com
terrapinn.com/EAC2015


Aperçu du document European-Antibody-Congress-brochure.pdf - page 1/27
 
European-Antibody-Congress-brochure.pdf - page 3/27
European-Antibody-Congress-brochure.pdf - page 4/27
European-Antibody-Congress-brochure.pdf - page 5/27
European-Antibody-Congress-brochure.pdf - page 6/27
 




Télécharger le fichier (PDF)


Télécharger
Formats alternatifs: ZIP




Documents similaires


european antibody congress brochure
july 2018 presse release npg
personnalized medicine program f
jcrreport2019 2020
eiu agent of change web final
recombinant dna and solar climate engineering

Sur le même sujet..




🚀  Page générée en 0.088s